Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN)

• Status: Completed
• Trial end date: 2018-03-01
• Target enrollment: 0
• Participant gender: All

Summary

A multi-center, randomized, double-blind, active-controlled, parallel group, phase IV clinical trial to investigate the effect on blood glucose of evogliptin after oral administration in patients with type 2 diabetes

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dong-A ST Co., Ltd.
• Treatments: Linagliptin

Criteria

Inclusion Criteria:

• Subjects with 7.0%≤HbA1c≤10.0% at screening

• Subjects untreated with oral hypoglycemic agents within 8 weeks prior to screening

• Subjects with 20kg/m2≤BMI≤40kg/m2 at screening

Exclusion Criteria:

• Subjects with fasting plasma glucose≥270mg/dL at screening

• Patients with type 1 diabetes mellitus, secondary diabetes mellitus or gestational diabetes mellitus

• Subjects with history of myocardial infarction, cerebral infarction within 24 weeks prior to screening

• Subjects with ALT and AST 3 times or higher than upper normal range